All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-08-08T14:56:17.000Z

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

Aug 8, 2024
Share:
Learning objective: After reading this article, learners will be able to discuss maintenance therapy in patients with AML who are in remission post intensive chemotherapy and not proceeding to transplant.

Bookmark this article

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission post intensive chemotherapy?

Figure 1. Case study presentation: Patient characteristics and treatment history 

AML, acute myeloid leukemia; CR, complete remission; ECOG, Eastern Cooperative Oncology Group; HSCT, hematopoietic stem cell transplantation.


Papayannidis discusses a case of a 67-year-old female with DNMT3A-mutated AML who achieved remission following intensive chemotherapy. Her comorbidities and advanced age make her ineligible for allogenic hematopoietic stem cell transplant (allo-HSCT) and create a need for maintenance therapy options. Papayannidis recalls the key findings from the phase III QUAZAR AML-001 (NCT01757535) study, published by Wei et al.1 in the New England Journal of Medicine, evaluating oral azacitidine vs placebo in patients with AML ineligible for allo-HSCT. Papayannidis also reviews the post hoc subgroup analysis of this trial presented by Lopes De Menezes2 at ASH 2023, which evaluated the efficacy of oral azacitidine in various mutational subgroups, to guide her treatment approach. She concludes that, for patients not proceeding to allo-HSCT after chemotherapy, oral azacitidine is an important treatment option that is effective in all subgroups of AML, in particular in those with DNMT3A and SRSF2 mutations.

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

Listen to the podcast here:

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy


I commit to consider the latest data on oral azacitidine maintenance therapy to guide my treatment of AML in clinical practice.

Agree

100%

Disagree

0%

3 votes


This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource 

  1. Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526-2537. DOI: 1056/NEJMoa2004444.
  2. Lopes De Menezes D. Clonal dynamics of gene mutations during oral azacitidine maintenance therapy in patients with acute myeloid leukemia (AML): Outcomes from the QUAZAR AML-001 trial. Poster abstract #1582. 65th American Society of Hematology Annual Meeting and Exposition; Dec 9, 2023; San Diego, US.

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
21 votes - 70 days left ...

Related articles

Newsletter

Subscribe to get the best content related to AML delivered to your inbox